Click below to register.

Wednesday, October 10th, 2018

Hilton New Orleans Riverside

Two Poydras Street
New Orleans, LA

Room: Grand Salon B

Registration and Dinner 6:00 PM – 6:30 PM
Interactive CME Activity 6:30 PM – 8:00 PM

This educational activity is supported by an educational grant from GlaxoSmithKline.

This event is not part of the official AAFP FMX.

Management of chronic obstructive pulmonary disease (COPD), a complex, heterogeneous disease, has been complicated by new recommendations that incorporate novel escalation strategies with dual bronchodilation treatments. Fixed-dose combination (FDC) dual bronchodilation, consisting of a long-acting ß agonist (LABA) combined with a long-acting muscarinic antagonist (LAMA), has emerged as an effective strategy for patients who require escalation beyond LABA or LAMA monotherapy, with an emphasis on outcomes beyond lung function, including reducing exacerbations. For patients who require escalation beyond LAMA/LABA or other dual therapies, there is now a fixed-dose, once-daily triple therapy (LAMA/LABA/inhaled corticosteroid [ICS]) inhaler. Despite updated recommendations, limited practical guidance on individualizing therapy or identifying patients who may benefit from treatment escalation (ie, escalating from mono- to dual bronchodilation therapy or adding an ICS/escalating to triple therapy) exists. In addition, lack of knowledge of appropriate COPD inhaler choice/use and self-management strategies persists, precluding optimal therapeutic benefit and clinical outcomes. This live, interactive activity will feature 3 experts in COPD, who will review and discuss the clinical science behind dual bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

The goal of this CME activity is for physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD in primary care settings to develop the knowledge base to incorporate recommended dual and triple brochodilation management strategies into their practice and to improve individualized treatment plans for their COPD patients.

After completing this activity, the participant should be better able to:
  • EVALUATE the scientific evidence supporting the use of dual bronchodilation & triple drug therapy.
  • UTILIZE the most up to date COPD recommendations on treatment initiation, including inhaler device selection.
  • REVIEW content and timing of follow up visits and strategies to modify therapy.
  • EMPLOY strategies that provide disease education & inhaler training to patients with COPD.
  • DEVELOP individualized COPD maintenance treatment strategies using a COPD Action Plan.
Continuing Education Information


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Activity Registration and Dinner

Activity Overview and Goals

Burden, Diagnosis, and Initial Treatment of COPD, with an Emphasis on Dual Therapy

Outcomes Other than Exacerbations and How They Are Measured

Advances in Triple Therapy: The Advent of Single-Inhaler Treatment Options and the Continuing Role of Pulmonary Rehabilitation

Assessing the Most Up-to-Date COPD Recommendations: Escalation of Therapy and Step-Down Therapy

Implementing Individualized Treatment Plans, with a Discussion of COPD Action Plans

Improving Inhaler Selection and Observing Inhaler Technique

Conclusions and Postassessment

This schedule is subject to change.

Barbara P. Yawn, MD, MSc, FAAFP (Chair)
Adjunct Professor
Department of Family and Community Health
University of Minnesota
Minneapolis, Minnesota
Chief Science Officer of the COPD Foundation Miami, Florida

Stephen A. Brunton, MD
Executive Director
Primary Care Respiratory Group
Palm Springs California

This educational initiative is designed for physicians, physician assistants, nurse practitioners, and nurses engaged in the care of patients with COPD in primary care settings.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act (ADA)
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Adrienne Roser prior to the live event at 908-253-9001 ext. 23.

There is no fee for this educational activity.

Submit a case to review at meeting:

<img src="" alt="procced to pretest" border="0" />

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us